Total Payments
$12,628
2024 Payments
$1,725
Companies
52
Transactions
646
Medicare Patients
7,666
Medicare Billing
$1.3M
Payment Breakdown by Category
Food & Beverage$11,204 (88.7%)
Travel$1,077 (8.5%)
Education$346.93 (2.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,204 | 638 | 88.7% |
| Travel and Lodging | $1,077 | 2 | 8.5% |
| Education | $346.93 | 6 | 2.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $2,077 | 143 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,353 | 76 | $0 (2024) |
| Covidien LP | $1,101 | 3 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $682.68 | 39 | $0 (2024) |
| GENZYME CORPORATION | $548.90 | 26 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $532.38 | 24 | $0 (2024) |
| Grifols USA, LLC | $465.62 | 16 | $0 (2024) |
| Genentech USA, Inc. | $443.71 | 25 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $419.76 | 21 | $0 (2024) |
| Philips Electronics North America Corporation | $400.50 | 29 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,725 | 69 | ANI Pharmaceuticals, Inc. ($294.13) |
| 2023 | $1,739 | 77 | GlaxoSmithKline, LLC. ($332.80) |
| 2022 | $1,214 | 57 | AstraZeneca Pharmaceuticals LP ($205.47) |
| 2021 | $1,001 | 63 | Mallinckrodt Hospital Products Inc. ($228.88) |
| 2020 | $1,339 | 74 | GlaxoSmithKline, LLC. ($332.79) |
| 2019 | $1,352 | 91 | GlaxoSmithKline, LLC. ($225.73) |
| 2018 | $1,722 | 114 | AstraZeneca Pharmaceuticals LP ($286.16) |
| 2017 | $2,537 | 101 | Covidien LP ($1,101) |
All Payment Transactions
646 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/22/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 12/20/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: RESPIRATORY | ||||||
| 12/19/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $28.75 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $20.01 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/10/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $30.10 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.29 | General |
| Category: Immunology | ||||||
| 11/22/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $29.30 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 11/20/2024 | Philips North America LLC | (AK6) Vest Therapy (Device) | Food and Beverage | Cash or cash equivalent | $14.95 | General |
| Category: Medical Device | ||||||
| 11/19/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $25.86 | General |
| Category: Inflammation | ||||||
| 11/14/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.33 | General |
| Category: Immunology | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/30/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $33.88 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/29/2024 | La Jolla Pharmaceutical Company | GIAPREZA (Drug) | Food and Beverage | In-kind items and services | $20.62 | General |
| Category: EMERGENT HYPOTENSION | ||||||
| 10/28/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $30.24 | General |
| Category: RESPIRATORY | ||||||
| 10/24/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $21.48 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/23/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $63.22 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 10/03/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: NEUROLOGY | ||||||
| 10/01/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: IMMUNOLOGY | ||||||
| 09/27/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: VACCINES | ||||||
| 09/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO RESPIMAT (Drug), SPIRIVA RESPIMAT | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: RESPIRATORY | ||||||
| 09/25/2024 | Vifor Pharma, Inc. | Zemaira (Drug) | Food and Beverage | In-kind items and services | $27.13 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 09/25/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $14.43 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,584 | 2,555 | $696,596 | $268,705 |
| 2022 | 17 | 1,666 | 2,657 | $697,855 | $282,036 |
| 2021 | 16 | 1,959 | 3,225 | $859,035 | $355,946 |
| 2020 | 19 | 2,457 | 3,700 | $846,309 | $354,360 |
Total Patients
7,666
Total Services
12,137
Medicare Billing
$1.3M
Procedure Codes
78
All Medicare Procedures & Services
78 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 235 | 609 | $280,140 | $99,788 | 35.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 407 | 727 | $140,311 | $65,426 | 46.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 164 | 318 | $59,466 | $29,151 | 49.0% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 33 | 33 | $49,500 | $15,146 | 30.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 98 | 104 | $37,648 | $13,549 | 36.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 98 | 161 | $21,735 | $9,781 | 45.0% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 15 | 15 | $24,000 | $7,053 | 29.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 42 | 42 | $15,498 | $6,832 | 44.1% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 100 | 112 | $11,760 | $4,761 | 40.5% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 96 | 107 | $12,305 | $4,247 | 34.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 27 | $6,993 | $3,570 | 51.1% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 103 | 114 | $12,768 | $3,196 | 25.0% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 91 | 102 | $10,035 | $2,579 | 25.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 26 | 31 | $4,092 | $2,041 | 49.9% |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | Office | 2023 | 19 | 21 | $6,825 | $1,328 | 19.5% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 16 | 16 | $1,840 | $147.68 | 8.0% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 16 | 16 | $1,680 | $109.44 | 6.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 280 | 783 | $360,180 | $133,468 | 37.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 359 | 547 | $89,896 | $47,964 | 53.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 206 | 397 | $71,460 | $31,674 | 44.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 116 | 122 | $40,260 | $19,005 | 47.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 133 | 216 | $29,160 | $12,039 | 41.3% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2022 | 13 | 13 | $19,500 | $6,339 | 32.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 40 | 40 | $12,200 | $6,083 | 49.9% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2022 | 12 | 12 | $18,710 | $6,011 | 32.1% |
About Dr. Manojkumar Patel, MD
Dr. Manojkumar Patel, MD is a Pulmonary Disease healthcare provider based in Chesapeake, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1396953469.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Manojkumar Patel, MD has received a total of $12,628 in payments from pharmaceutical and medical device companies, with $1,725 received in 2024. These payments were reported across 646 transactions from 52 companies. The most common payment nature is "Food and Beverage" ($11,204).
As a Medicare-enrolled provider, Patel has provided services to 7,666 Medicare beneficiaries, totaling 12,137 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 78 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Chesapeake, VA
- Active Since 05/20/2007
- Last Updated 04/25/2017
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1396953469
Products in Payments
- superDimension (Device) $1,101
- NUCALA (Biological) $1,040
- ACTHAR (Biological) $664.35
- DUPIXENT (Biological) $638.14
- TRELEGY ELLIPTA (Drug) $530.01
- PURIFIED CORTROPHIN GEL (Drug) $371.79
- Prolastin-C Liquid (Biological) $349.70
- OFEV (Drug) $335.19
- BEVESPI AEROSPHERE (Drug) $313.73
- Xolair (Biological) $304.18
- TEZSPIRE (Biological) $291.35
- XOLAIR (Biological) $247.58
- OPSUMIT (Drug) $244.73
- SYMBICORT (Drug) $243.79
- STIOLTO RESPIMAT (Drug) $219.89
- FASENRA (Biological) $212.16
- BREZTRI (Drug) $206.17
- NUZYRA (Drug) $202.97
- FASENRA (Drug) $193.38
- ANORO (Drug) $191.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Chesapeake
Carlos Silva, M.d, M.D
Pulmonary Disease — Payments: $281,208
Pulmonary Disease $281,208
Dr. Haresh Patel, M.d, M.D
Pulmonary Disease — Payments: $3,384
Pulmonary Disease $3,384
Dr. Michelle Perello, Do, DO
Pulmonary Disease — Payments: $3,348
Pulmonary Disease $3,348
Mrs. Vandana Patel, Md, MD
Pulmonary Disease — Payments: $3,037
Pulmonary Disease $3,037
Eric Freeman, Md, MD
Pulmonary Disease — Payments: $2,061
Pulmonary Disease $2,061
Leah Zuniega, Md, MD
Pulmonary Disease — Payments: $1,988
Pulmonary Disease $1,988